Intravenous pamidronate for refractory lymphedema

Area of Science:

• Pharmacology
• Vascular Medicine
• Clinical Therapeutics

Background:

• Pamidronate has shown efficacy in reducing pain and swelling associated with reflex sympathetic dystrophy.
• Refractory lymphedema presents a significant clinical challenge, necessitating novel treatment approaches.
• The potential of pamidronate as a novel therapeutic agent for lymphedema warrants investigation.

Purpose of the Study:

• To evaluate the therapeutic effectiveness of pamidronate in patients with refractory lower limb lymphedema.
• To assess the safety and potential side effects of pamidronate administration for lymphedema.

Main Methods:

• A cohort of twelve patients with lower limb refractory lymphedema was enrolled in the study.
• Participants received monthly intravenous pamidronate infusions over three consecutive months.
• Outcomes were assessed using the Visual Analog Scale (VAS) for discomfort, physician global assessment, limb volume, and circumference measurements.

Main Results:

• Significant improvements were observed in limb volume and circumference.
• Patient-reported satisfaction levels demonstrated a significant increase post-treatment.
• Pamidronate administration was associated with positive clinical outcomes in refractory lymphedema.

Conclusions:

• Pamidronate, when integrated with conservative management strategies, demonstrates potential in reducing lymphedema.
• The addition of pamidronate may enhance patient comfort and clinical outcomes in lymphedema management.
• Further research is warranted to establish optimal dosing and long-term efficacy.